| Kalium Group of Companies set for unrivalled presence at Dubai Derma 2008
Kalium Group of Companies, one of the fastest growing distributors of advanced Medical Equipment, Skin Care Products and Aesthetic Devices in the Middle East, has announced that it will have a significant presence at the Dubai Derma 2008 exhibition for the third consecutive year. .
Contact with mother's skin relieves preemie's pain
A new study suggests that very premature babies, born between 28 and 31 weeks, benefit from skin-to-skin contact with their mothers before and during painful procedures. Skin-on-skin contact between a mother and her baby, commonly known as kangaroo mother care, has been proven to be effective at relieving pain among preemies born between 32 and 36 weeks. However, the common assumption has been that it could not work on very premature babies because they are too underdeveloped to benefit from it. The team from McGill University in Montreal that proved the effectiveness of KMC for the older preemies decided to test its effectiveness on the younger ones. They analyzed whether KMC could help the littlest preemies recover from the pain of a heel lance, where blood is drawn from a baby's heel.
Helix BioMedix Announces U.S. Patent Issuance for Cosmetic Compositions Containing Short Bioactive Peptides
Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced that it has been issued U.S. Patent number 7,354,903 by the United States Patent and Trademark Office. The patent covers more than eighty proprietary peptides for use in cosmetic and skin care applications and products. There are currently over 20 marketed products using peptides protected under the patent including such cosmeceutical brands as Fusion Beauty, Smashbox, Isomers, and B. Kamins. Numerous additional product roll outs are planned for later this year. "The issuance of this patent is a key step in the protection of the intellectual property associated with our proprietary peptides, which is of critical importance to the company," stated R. Stephen Beatty, President and CEO of Helix BioMedix, Inc.
|
